Pipeline & Partnering
Fosun Pharma USA established a dedicated team with:
Ready to work with agility:
In March 2020, BioNTech granted Fosun Pharma exclusive right to develop and commercialize COVID-19 vaccines based on its mRNA technology platform in the Chinese Mainland, Hong Kong SAR, Macau SAR and Taiwan region. By the end of Feb, 2022, more than 20 million COMIRNATY® (mRNA COVID-19 vaccine) has been administered in Hong Kong, Macau and Taiwan, helping to establish the COVID-19 barrier in the region.
As a joint venture between Shanghai Fosun Pharmaceutical (Group) Co., Ltd and Kite, a Gilead company in U.S., Fosun Kite is dedicated to the advancement of cell therapy and its commercialization to benefit cancer patients in China. Fosun Kite has a commercial manufacturing facility of approximately 10,000 m2, and a R&D center of 2,000 m2 with a professionally experienced R&D team. Taking a combined approach of internal R&D effort and external partnering, Fosun Kite has built a sustainable pipeline including CAR-T programs at both discovery and clinical stages.